Feature | April 08, 2011

Drug-Eluting Stents Improve Outcomes in Saphenous Vein Graft Lesions

In the largest randomized, multicenter trial to compare drug-eluting stents (DES) and bare-metal stents (BMS) placed in saphenous vein graft lesions, researchers found that DES led to a lower combined rate of death, heart attack and repeat revascularization. The research findings were presented this week at the American College of Cardiology’s 60th Annual Scientific Session.

While saphenous vein grafts (SVGs) have been used extensively in coronary artery bypass graft (CABG) surgery, these conduits often develop atherosclerotic disease that results in vessel narrowing or closure. Conducting a second CABG surgery to fix the graft is possible but can result in higher mortality and morbidity rates than the first operation. Performing angioplasty with a stent is an alternative to repeat CABG surgery, and research is still being conducted to optimize this procedure.

“DES have proven superior to BMS in all coronary artery lesion subsets examined, but their performance has been insufficiently evaluated in SVG lesions,” said Julinda Mehilli, M.D., director of clinical research and data coordinating in the Intracoronary Stenting and Antithrombosis Research (ISAR) Center at the German Heart Center Munich, Germany. “The only two very small randomized trials comparing DES with BMS in SVG lesions provided conflicting results. Thus, the aim of the ISAR-CABG trial was to investigate this question in a larger population sufficiently powered to provide information on clinical endpoints.”

For the study, German researchers enrolled 610 patients who had previously undergone CABG surgery. All study patients had subsequently developed at least one lesion in their saphenous vein graft and were randomized to receive either a DES (n = 303) or a BMS (n = 307) in the study angioplasty procedure.

The study’s primary endpoint was a composite of major adverse cardiac events, including death, heart attack, and target-lesion revascularization (TLR) at the one-year follow-up point. The secondary endpoints were the individual rates of death, heart attack, Academic Research Consortium (ARC) definite stent thrombosis and the need for TLR over one year.

The researchers found that the incidence of major adverse cardiac events was reduced by 35 percent in the DES cohort compared to the BMS group. Specifically, 16.5 percent of patients in the DES group experienced the primary endpoint compared with 22.1 percent of patients in the BMS group (hazard ratio [HR] 0.65; 95 percent confidence interval [CI] 0.45 – 0.96; p = 0.028). The reduction in the DES group was primarily due to a significantly lower rate of TLR, which occurred in 7.2 percent of patients in the DES group and in 12.9 percent of patients in the BMS group (HR 0.52; 95 percent CI 0.3 – 0.9; p = 0.020).

The research team found no significant differences in the individual rates of death or heart attack. Additionally, only one patient in the DES cohort experienced ARC-definite stent thrombosis. None of the patients in the BMS group experienced this outcome.

“Saphenous vein graft lesions remain a challenging disease subset for angioplasty. The ISAR-CABG trial, however, demonstrates that DES can safely be used to reduce adverse events in this high-risk subset of patients,” Mehilli said.

The study was funded by the German Heart Center Munich and by Cordis. Mehilli had no disclosures to report.

For more information: www.cardiosource.org

Related Content

First European Patient Enrolled in Intact Vascular's TOBA II BTK Trial
News | Stents Peripheral| July 26, 2017
Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
New York Hospital Finds Significant Cost Savings With Toshiba's Aquilion One CT
News | Computed Tomography (CT)| July 25, 2017
July 25, 2017 — In five years, Kaleida Health’s Stroke Care Center (SCC) at the Gates Vascular Institute in Buffalo,
Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies| July 25, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are
New PET-CT Scan Improves Detection in Rare Cardiac Condition
News | PET-CT| July 25, 2017
Using a new imaging technique that can diagnose cardiac sarcoidosis much more accurately than traditional tests,...
Sponsored Content | Videos | Peripheral Arterial Disease (PAD)| July 25, 2017
This video case study, provided by Gore Medical, it titled "Tackling Complex Cases in Dialysis Access," by John Ross,
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Hospital Readmissions Analysis Across All Ages, Insurance Types Identifies High-Risk Groups
News | Business| July 20, 2017
July 20, 2017 — Clinician-researchers at Beth Israel Deaconess Medical Center (BIDMC) recently published a first-of-i
3-D Vascular Ultrasound Quantifies Plaque Burden to Estimate Cardiovascular Risk
News | Cardiovascular Ultrasound| July 20, 2017
July 20, 2017 — In a large, first-of-its-kind population, researchers found an experimental technique known as...
More Than 20 Percent of Low-Risk Patients Receive Annual ECG
News | ECG| July 20, 2017
July 20, 2017 — More than one in five Ontario patients receive an ...
Sponsored Content | Videos | Cardiovascular Surgery| July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Overlay Init